Guizhou Sanli Pharmaceutical Co Ltd (SHG:603439) — Market Cap & Net Worth
Market Cap & Net Worth: Guizhou Sanli Pharmaceutical Co Ltd (603439)
Guizhou Sanli Pharmaceutical Co Ltd (SHG:603439) has a market capitalization of $865.28 Million (CN¥5.91 Billion) as of September 24, 2026. Listed on the SHG stock exchange, this China-based company holds position #9669 globally and #2506 in its home market, demonstrating a 4.86% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Guizhou Sanli Pharmaceutical Co Ltd's stock price CN¥14.46 by its total outstanding shares 408930216 (408.93 Million). Also see Guizhou Sanli Pharmaceutical Co Ltd balance sheet assets for a full breakdown of the balance sheet.
Guizhou Sanli Pharmaceutical Co Ltd Market Cap History: 2020 to 2026
Guizhou Sanli Pharmaceutical Co Ltd's market capitalization history from 2020 to 2026. Data shows growth from $1.19 Billion to $865.28 Million (5.36% CAGR). Also see Guizhou Sanli Pharmaceutical Co Ltd operating cash flow efficiency for how efficiently the company converts equity into cash flow.
Guizhou Sanli Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Guizhou Sanli Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check 603439 stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.36x
Guizhou Sanli Pharmaceutical Co Ltd's market cap is 0.36 times its annual revenue
Latest Price to Earnings (P/E) Ratio
2.84x
Guizhou Sanli Pharmaceutical Co Ltd's market cap is 2.84 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $1.19 Billion | $630.22 Million | $93.95 Million | 1.88x | 12.63x |
| 2021 | $939.14 Million | $938.97 Million | $152.28 Million | 1.00x | 6.17x |
| 2022 | $816.54 Million | $1.20 Billion | $201.28 Million | 0.68x | 4.06x |
| 2023 | $1.13 Billion | $1.63 Billion | $292.70 Million | 0.69x | 3.86x |
| 2024 | $777.91 Million | $2.14 Billion | $274.03 Million | 0.36x | 2.84x |
Competitor Companies of 603439 by Market Capitalization
Companies near Guizhou Sanli Pharmaceutical Co Ltd in the global market cap rankings as of September 24, 2026. Review how tangible is Guizhou Sanli Pharmaceutical Co Ltd's equity to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Guizhou Sanli Pharmaceutical Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #524 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #586 globally with a market cap of $46.44 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #638 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #651 globally with a market cap of $42.68 Billion USD ( CN¥291.65 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #524 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #586 | GALDERMA GROUP AG | NYSE:GALDY | $46.44 Billion | $39.83 |
| #638 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.50 |
| #651 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $42.68 Billion | CN¥45.72 |
Guizhou Sanli Pharmaceutical Co Ltd Historical Marketcap From 2020 to 2026
Between 2020 and today, Guizhou Sanli Pharmaceutical Co Ltd's market cap moved from $1.19 Billion to $ 865.28 Million, with a yearly change of 5.36%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥865.28 Million | +23.59% |
| 2025 | CN¥700.12 Million | -10.00% |
| 2024 | CN¥777.91 Million | -31.14% |
| 2023 | CN¥1.13 Billion | +38.36% |
| 2022 | CN¥816.54 Million | -13.05% |
| 2021 | CN¥939.14 Million | -20.83% |
| 2020 | CN¥1.19 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 23rd, 2026 the market cap of Guizhou Sanli Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $865.28 Million USD |
| MoneyControl | $865.28 Million USD |
| MarketWatch | $865.28 Million USD |
| marketcap.company | $865.28 Million USD |
| Reuters | $865.28 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Guizhou Sanli Pharmaceutical Co Ltd
Guizhou Sanli Pharmaceutical Co.,Ltd, together with its subsidiaries, engages in the plantation, research, development, production, and sale of pharmaceutical products in China. The company offers respiratory system, tonic, gynecological, and orthopedic medications, as well as cardiovascular and cerebrovascular drugs, and other medicines. It also provides products in various dosage forms, includi… Read more